Research programme: asthma therapy - NexMed
Alternative Names: NM 100100; NM 20138Latest Information Update: 15 Sep 2010
At a glance
- Originator NexMed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute asthma
Most Recent Events
- 15 Sep 2010 Discontinued - Preclinical for Acute asthma in USA (Transdermal)
- 19 Jul 2004 Preclinical trials in Acute asthma in USA (Transdermal)